The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk

ABSTRACT Background: Decisions regarding diabetes management traditionally have been driven by the results of fasting plasma glucose measurement or measurement of glycosylated hemoglobin (A1C), yet glycemic control remains far from optimal in many individuals with diabetes. Mounting evidence implicates glycemic variability, manifested predominantly as postprandial glycemic spikes, as a key factor in the development of macrovascular complications. Recent studies suggest that newer therapies specifically targeting postprandial hyperglycemia can significantly reduce postprandial glucose levels and improve overall glycemic control. Methods: A Medline search was performed using the term ‘postchallenge’ or ‘postprandial’, together with glucose or diabetes. After excluding review articles and case studies, we reviewed primary articles, meta-analyses, and references therein and selected those that best addressed this topic. Selection bias may be considered a potential limitation of this approach. Findings: Although not conclusively demonstrated by prospective studies, a wealth of evidence suggests that postprandial hyperglycemia should not be ignored as an important target for preventing complications of diabetes. Conclusions: Improved detection and management of postprandial hyperglycemia and glycemic variability is necessary to optimize glycemic control. Meal-based self-monitoring of blood glucose (SMBG) has been shown to improve glycemic control as part of a comprehensive management strategy by helping patients understand the effects of food choices, physical activity, and medications on blood glucose concentrations. SMBG can also help healthcare professionals recognize postprandial hyperglycemia, guide therapeutic adjustments and receive more timely feedback regarding medication changes. The arrival of new therapies that specifically target postprandial hyperglycemia offer healthcare professionals the opportunity to optimally manage diabetes.

[1]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[2]  C. Weyer,et al.  Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.

[3]  L. Bouter,et al.  Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. , 2005, Diabetes care.

[4]  M. Taskinen,et al.  What does postprandial hyperglycaemia mean? , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[5]  E. Bonora,et al.  Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence , 2001, Diabetologia.

[6]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[7]  M. Abrahamson.  Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. , 2004, Archives of internal medicine.

[8]  M. Nauck,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial , 2007, Diabetes, obesity & metabolism.

[9]  Kathryn Tan,et al.  Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004)* , 2005, Current medical research and opinion.

[10]  J. Gerich.  Clinical significance, pathogenesis, and management of postprandial hyperglycemia. , 2003, Archives of internal medicine.

[11]  Yan Wang,et al.  Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. , 2003, Diabetes care.

[12]  S. Del Prato.  In search of normoglycaemia in diabetes: controlling postprandial glucose , 2002, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[13]  M. Shichiri,et al.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.

[14]  A. Cavarape,et al.  The post‐prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[15]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[16]  L. Jaber,et al.  Evaluation of a Pharmaceutical Care Model on Diabetes Management , 1996, The Annals of pharmacotherapy.

[17]  R. McCarter,et al.  Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. , 2006, Diabetes care.

[18]  Hee-Seung Kim,et al.  Establishment of blood glucose monitoring system using the internet. , 2003, Diabetes care.

[19]  H. Kaneto,et al.  Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. , 2005, Biochemical and biophysical research communications.

[20]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[21]  T. Nakagami,et al.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin , 2004, Diabetologia.

[22]  E. Bonora,et al.  Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. , 2001, Diabetes care.

[23]  Howard Zisser,et al.  Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. , 2006, Diabetes care.

[24]  S. Prato.  In search of normoglycaemia in diabetes: controlling postprandial glucose , 2002, International Journal of Obesity.

[25]  W. Tamborlane,et al.  Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. , 2001, Diabetes care.

[26]  L. Jovanovic,et al.  Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values , 2006, Diabetes Care.

[27]  G. Mertes,et al.  Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. , 2002, Diabetes care.

[28]  S. Besuschio,et al.  Evaluation of innovative skin-marking technique performed before thyroid ultrasound-guided fine-needle aspiration biopsies. , 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[29]  R. Marfella,et al.  Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus , 2004, Circulation.

[30]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[31]  C. Weyer,et al.  Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. , 2002, Diabetes technology & therapeutics.

[32]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[33]  J. McGarry.  Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.

[34]  H. Funato,et al.  Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control , 1996, The Lancet.

[35]  R. Bergenstal,et al.  The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. , 2005, The American journal of medicine.

[36]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[37]  G. Tognoni,et al.  The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus A model of medicine-based evidence , 1999, European Journal of Clinical Pharmacology.

[38]  D. Muchmore,et al.  Self-monitoring of blood glucose in overweight type 2 diabetic patients , 1994, Acta Diabetologica.

[39]  C. Beebe.  Self blood glucose monitoring: an adjunct to dietary and insulin management of the patient with diabetes. , 1987, Journal of the American Dietetic Association.

[40]  I. Hirsch,et al.  Should minimal blood glucose variability become the gold standard of glycemic control? , 2005, Journal of diabetes and its complications.

[41]  M. Hanefeld,et al.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.

[42]  M. Davidson,et al.  Counterpoint: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money. , 2005, Diabetes care.

[43]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[44]  J. Foley,et al.  Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response , 2005, Diabetes, obesity & metabolism.

[45]  T. Erlinger,et al.  Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. , 2001, Diabetes care.

[46]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[47]  Y. Akanuma,et al.  Plasma 1,5-Anhydro-D-Glucitol as New Clinical Marker of Glycemic Control in NIDDM Patients , 1989, Diabetes.

[48]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[49]  C. Parkin,et al.  Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings? , 2002 .

[50]  Beebe Ca.  Self blood glucose monitoring: an adjunct to dietary and insulin management of the patient with diabetes. , 1987 .

[51]  Michael Brownlee,et al.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. , 2006, JAMA.

[52]  J. Leahy,et al.  Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§ , 2006 .

[53]  Claude Colette,et al.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). , 2003, Diabetes care.

[54]  S. Martin,et al.  Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study , 2006, Diabetologia.

[55]  E. Ogata,et al.  Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. , 2001, Clinical science.

[56]  G. Fulcher,et al.  Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. , 2003, Diabetes technology & therapeutics.

[57]  A. Berghold,et al.  Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus , 2006 .

[58]  American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control * , 2004 .

[59]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[60]  A. Krikorian,et al.  Standards of medical care in diabetes--2006. , 2006, Diabetes care.

[61]  T. Md.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin , 2004, Diabetologia.

[62]  V. Mohan,et al.  Postprandial Hyperglycemia in Patients with Type 2 Diabetes Mellitus , 2002, Treatments in Endocrinology.

[63]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[64]  K. Mann,et al.  Follow-up Intervention: Its Effect on Compliance Behavior to a Diabetes Regimen , 1990, The Diabetes educator.